Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Watch our expert webinar Radical cure of P. vivax: can we do better?

The webinar took place earlier this month and featured two new studies using WWARN-hosted clinical trial data showing that the dosing of the 8-aminoquinolin drugs primaquine and tafenoquine can be substantially improved. These analyses include the majority of all studied vivax malaria patients who received 8-aminoquinoline drugs over the last 20 years. Laboratory work confirms these findings and provides important new information on the mechanism of action of these essential medicines.

  • Dr Rob Commons, Menzies School of Health Research, on 8AQ efficacy in clinical trials
  • Dr Alison Roth, Walter Reed Army Institute of Research, on laboratory studies assessing hypnozoitocidal activity
  • Dr James Watson, Oxford University Clinical Research Unit, on the reassessment of tafenoquine pharmacometrics

Videos of the three webinar presentations are available on our TropMed Webinars page

Read the publication 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis' on the elife website

The full story is available on the IDDO website

 

Similar stories

Simple new method that measures viral clearance means antibody treatments for COVID and ‘flu can be quickly assessed for effectiveness, say MORU researchers

Measuring the rate of viral clearance from the back of the mouth in patients with mild infections can be used to determine quickly and inexpensively if an antibody is effective in future COVID-19, influenza and other respiratory virus pandemics, say researchers in a letter published today in The Lancet.